Modified guide RNA

HK40137366APending Publication Date: 2026-09-11BEAM THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124711
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-28
Filing Date
2026-06-11
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention relates to modified gRNA molecules, compositions and methods for site specific gene editing and genomic modification, such as DNA cleavage, and gene activation or repression. The present modified guide RNAs have modified secondary structure (e.g., long upper stem and a modified hairpin structure), which target the target DNA sequence specifically with reduced off-target activity.
Need to check novelty before this filing date? Find Prior Art

Description

Abstract This invention relates to modified gRNA molecules, compositions, and methods for site-specific gene editing and genome modification (e.g., DNA cleavage, gene activation, or repression). The modified guide RNAs of this invention have modified secondary structures (e.g., a longer upper stem and a modified hairpin structure) that enable them to specifically target DNA sequences and reduce off-target activity.

Claims

Attorney Docket No. BEM-020WO1 CLAIMS 1. A single guide RNA (sgRNA) comprising a long (or extended) upper stem including more than 4 base pairs formed by complementary nucleotides, wherein one or more nucleotides of the upper stem are modified nucleotides.

2. The sgRNA of claim 1, wherein the long upper stem region comprises 5-15 base pairs formed by complementary nucleotides.

3. The sgRNA of claim 2, wherein the long upper stem region comprises 5 base pairs formed by complementary nucleotides.

4. The sgRNA of claim 2, wherein the long upper stem region comprises 6 base pairs formed by complementary nucleotides.

5. The sgRNA of claim 2, wherein the long upper stem region comprises 7 base pairs formed by complementary nucleotides.

6. The sgRNA of claim 2, wherein the long upper stem region comprises 8 base pairs formed by complementary nucleotides.

7. The sgRNA of claim 2, wherein the long upper stem region comprises 9 base pairs formed by complementary nucleotides.

8. The sgRNA of claim 2, wherein the long upper stem region comprises 10 base pairs formed by complementary nucleotides.

9. The sgRNA of any one of the preceding claims, wherein all the nucleotides of the upper stem are modified nucleotides.

10. The sgRNA of any one of the preceding claims, wherein one or more nucleotides within the hairpin 1 and hairpin 2 regions are modified nucleotides.

11. The sgRNA of claim 10, wherein all of the nucleotides within the hairpins 1 and 2 regions are modified nucleotides.Attorney Docket No. BEM-020WO1 12. The sgRNA of any one of the preceding claims, wherein the sgRNA further comprises a modified stable hairpin 1 region.

13. The sgRNA of claim 12, wherein the modified stable hairpin 1 region comprises an extended stem region comprising more than 4 base pairs and wherein the loop of hairpin 1 comprises locked nucleic acid.

14. A guide RNA comprising an extended upper stem including more than 4 base pairs formed by complementary nucleotides, wherein the nucleotides within the upper stem comprise 2’-O methyl modification.

15. A single guide RNA (sgRNA) comprising a sequence of GUUUUAGA NxnGAAA NynAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU CGGUGCUUUU (SEQ ID NO.1), wherein Nxnand Nynhave the same number of nucleotides and are complementary nucleotides to form base pairs, and wherein the nucleotides of Nxn and Nyn are modified nucleotides, and wherein n is an integral number from 5-15.

16. The sgRNA of claim 15, wherein the Nx and Ny include 5 nucleotides respectively that are complementary nucleotides and that form the upper stem region of the sgRNA, and wherein the sgRNA comprises the sequence of GUUUUAGANxNxNxNxNxGAAANyNyNyNyNyAAGUUAAAAUAAGGCUAGUCCGUUA UCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO:2) 17. The sgRNA of claim 15, wherein the Nx and Ny include 6 nucleotides respectively that are complementary nucleotides and that form the upper stem region of the sgRNA, and wherein the sgRNA comprises the sequence of GUUUUAGANxNxNxNxNxNxGAAANyNyNyNyNyNyAAGUUAAAAUAAGGCUAGUCCG UUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO:3) 18. The sgRNA of claim 15, wherein the Nx and Ny include 7 nucleotides respectively that are complementary nucleotides and that form the upper stem region of the sgRNA, and wherein the sgRNA comprises the sequence of GUUUUAGANxNxNxNxNxNxNxGAAANyNyNyNyNyNyNyAAGUUAAAAUAAGGCUAGU CCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO:4) 19. The sgRNA of claim 15, wherein the Nx and Ny include 8 nucleotides respectively that are complementary nucleotides and that form the upper stem region of the sgRNA, andAttorney Docket No. BEM-020WO1 wherein the sgRNA comprises the sequence of GUUUUAGANxNxNxNxNxNxNxNxGAAANyNyNyNyNyNyNyNyAAGUUAAAAUAAGGCU AGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO:5) 20. The sgRNA of claim 15, wherein the Nx and Ny include 9 nucleotides respectively that are complementary nucleotides and that form the upper stem region of the sgRNA, and wherein the sgRNA comprises the sequence of GUUUUAGANxNxNxNxNxNxNxNxNxGAAANyNyNyNyNyNyNyNyNyAAGUUAAAAUAAG GCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 6).

21. The sgRNA of claim 15, wherein the Nx and Ny include 10 nucleotides respectively that are complementary nucleotides and that form the upper stem region of the sgRNA, and wherein the sgRNA comprises the sequence of GUUUUAGANxNxNxNxNxNxNxNxNxNxGAAANyNyNyNyNyNyNyNyNyNyAAGUUAAAAU AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7).

22. The sgRNA of claim 15, wherein the sgRNA comprising the sequence of GUUUUAGAGCGCGGAAACGCGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAAC UUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 8).

23. The sgRNA of claim 14, wherein the sgRNA comprising the sequence of GUUUUAGAGCCGGCGGAAACGCCGGCAAGUUAAAAUAAGGCUAGUCCGUUAU CAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 9).

24. The sgRNA of any one of claims 14-23, wherein all the nucleotides within the upper stem comprise 2’O-methyl modification.

25. The sgRNA of claim 24, wherein the sgRNA comprises a sequence as set forth in any one of SEQ ID NOs: 20-32 and 51-52.

26. The sgRNA of any one of claims 14-25, wherein one or more nucleotides within the hairpin 1 and hairpin 2 regions are modified nucleotides.Attorney Docket No. BEM-020WO1 27. The sgRNA of claim 26, wherein all of the nucleotides within the hairpin 1 and hairpin 2 regions are modified nucleotides.

28. The sgRNA of any one of claims 14-27, wherein the loop of hairpin 1 comprises 2′-O- methyl modified nucleotides (e.g., 2′-O-methyl 3′-phosphorothioate (MS) nucleotide, 2′-O- methyl 3′-thioPACE (MSP) nucleotide), 2’-F modified nucleotides, locked nucleic acid, MOE (methoxyethyl), DNA nucleotides functionalized for conjugation, and a combination thereof.

29. A single guide RNA (sgRNA) comprising a sequence of GUUUUAGANxnGAAANynAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGGAC UUUGGUCCAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 10), wherein Nxn and Nyn have the same number of nucleotides and are complementary nucleotides to form base pairs, and wherein the nucleotides of Nxnand Nynare modified nucleotides and wherein n is an integral number from 5-15.

30. The sgRNA of claim 29, wherein the Nx and Ny include 5 nucleotides respectively that are complementary nucleotides and that form the upper stem region of the sgRNA, and wherein the sgRNA comprises the sequence of GUUUUAGANxNxNxNxNxGAAANyNyNyNyNy AAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGGACUUUGGUCCAAGUGGCA CCGAGUCGGUGCUUUU (SEQ ID NO: 11).

31. The sgRNA of claim 29, wherein the Nx and Ny include 6 nucleotides respectively that are complementary nucleotides and that form the upper stem region of the sgRNA, and wherein the sgRNA comprises the sequence of GUUUUAGANxNxNxNxNxNxGAAANyNyNyNyNyNy AAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGGACUUUGGUCCAAGUGGCA CCGAGUCGGUGCUUUU (SEQ ID NO: 12).

32. The sgRNA of claim 29, wherein the Nx and Ny include 7 nucleotides respectively that are complementary nucleotides and that form the upper stem region of the sgRNA, and wherein the sgRNA comprises the sequence of GUUUUAGANxNxNxNxNxNxNxGAAANyNyNyNyNyNyNyAAGUUAAAAUAAGGCUAGU CCGUUAUCAACUUGGACUUUGGUCCAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 13).Attorney Docket No. BEM-020WO1 33. The sgRNA of claim 29, wherein the Nx and Ny include 8 nucleotides respectively that are complementary nucleotides and that form the upper stem region of the sgRNA, wherein the sgRNA comprises the sequence of GUUUUAGANxNxNxNxNxNxNxNxGAAANyNyNyNyNyNyNyNyAAGUUAAAAUAAGGCU AGUCCGUUAUCAACUUGGACUUUGGUCCAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 14).

34. The sgRNA of claim 29, wherein the Nx and Ny include 9 nucleotides respectively that are complementary nucleotides and that form the upper stem region of the sgRNA, and wherein the sgRNA comprises the sequence of GUUUUAGANxNxNxNxNxNxNxNxNxGAAANyNyNyNyNyNyNyNyNyAAGUUAAAAUAAG GCUAGUCCGUUAUCAACUUGGACUUUGGUCCAAGUGGCACCGAGUCGGUGCUU UU (SEQ ID NO: 15).

35. The sgRNA of claim 29, wherein the Nx and Ny include 10 nucleotides respectively that are complementary nucleotides and that form the upper stem region of the sgRNA, and wherein the sgRNA comprises the sequence of GUUUUAGANxNxNxNxNxNxNxNxNxNxGAAANyNyNyNyNy NyNyNyNyNyAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGGACUUUGGUCCA AGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 16).

36. The sgRNA of claim 29, wherein the sgRNA comprises the sequence of GUUUUAGAGCCGGCGGAAACGCCGGCAAGUUAAAAUAAGGCUAGUCCGUUAU CAACUUGGACUUCGGUCCAAGUUUUU (SEQ ID NO: 17).

37. A single guide RNA (sgRNA) comprising a sequence of GUUUUAGANxnGAAANynAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGGAC NzNzNzNzGUCCAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 18), wherein Nxn and Nyn have the same number of nucleotides and are complementary nucleotides to form base pairs, and wherein the nucleotides of Nxnand Nynare modified nucleotides and wherein n is an integral number from 5-15, and wherein the 4 nucleotides of the loop of hairpin 1 (NzNzNzNz) comprises a sequence of UUCG, CUUG or GCAA.

38. The sgRNA of any one of claims 29-37, wherein one or more nucleotides within the hairpin 1 and hairpin 2 regions are chemically modified nucleotides.Attorney Docket No. BEM-020WO1 39. The sgRNA of claim 38, wherein all of the nucleotides within the hairpin 1 and hairpin 2 regions are modified nucleotides.

40. The sgRNA of any one of claims 29-39, wherein the loop of hairpin 1 comprises locked nucleic acid.

41. The sgRNA of any one of the preceding claims, wherein the modifications include 2′-O- methyl modified nucleotides (e.g., 2′-O-methyl 3′-phosphorothioate (MS) nucleotide, 2′-O- methyl 3′-thioPACE (MSP) nucleotide), 2’-F modified nucleotides, locked nucleic acid, MOE (methoxyethyl), DNA nucleotides functionalized for conjugation, and a combination thereof.

42. The sgRNA of any one of the preceding claims, wherein at least one modification comprises a 2’-O’methyl (2’-O-Me) modified nucleotide.

43. The sgRNA of any one of claims 29-42, wherein all the nucleotides within the upper stem comprise 2’O-methyl modification.

44. The sgRNA of claim 43, wherein the sgRNA comprises a sequence as set forth in any one of SEQ ID NOs: 33 – 40.

45. The sgRNA of any one of the preceding claims, wherein the gRNA further comprises a spacer sequence at the 5′ end of the sgRNA; the spacer sequence comprises a sequence complementary to a target sequence of interest.

46. The sgRNA of claim 45, wherein the spacer sequence comprises about 18-25, or 18-30, or 20-25, or 20-30 nucleotides.

47. The sgRNA of any one of the preceding claims, wherein the 3’ end of the sgRNA is modified.

48. The sgRNA of any one of the preceding claims, wherein the 5′ end of the sgRNA is modified.

49. The sgRNA of claim 48, wherein at least the first three nucleotides at the 5′ end of the sgRNA is modified nucleotides.Attorney Docket No. BEM-020WO1 50. The sgRNA of any one of claims 1-46, wherein the sgRNA comprises a modification at the 5′ end of the sequence and a modification at the 3’ end of the sequence.

51. The sgRNA of any one of the preceding claims, wherein about 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 75%, 80%, 90% or 100% of the nucleotides of the sgRNA are modified nucleotides.

52. The sgRNA of any one of the preceding claims, wherein the sgRNA further comprises a nuclear localization sequence (NLS).

53. The sgRNA of any one of the preceding claims, wherein the sgRNA comprises about 102-150 nucleotides.

54. The sgRNA of claim 53, wherein the sgRNA comprises about 102-120 nucleotides.

55. The sgRNA of any one of the preceding claims, wherein the sgRNA increases the gene modification efficacy about 2 to 1000-fold.

56. The sgRNA of claim 55, wherein the sgRNA increases the gene modification efficacy about 2 to 100-fold, 2 to 50 fold, 2 to 20- fold or 10 to 50-fold.

57. The sgRNA of claim 56, wherein the sgRNA increases the gene modification efficacy about 2 to10-fold, 2 to5-fold, 3 to 8- fold, or 5 to10 fold.

58. A gene modification system comprising, (a) a CRISPR-associated protein (Cas) polypeptide, or variant thereof; and (b) a single guide RNA(sgRNA) of any one of the preceding claims.

59. The gene modification system of claim 58, wherein the Cas polypeptide is a Cas9 protein.

60. The gene modification system of claim 59, wherein the Cas9 is an S. pyogenes Cas9 or an S. aureus Cas9.

61. The gene modification system of claim 60, wherein the Cas9 polypeptide is a nickase or a dCas9.Attorney Docket No. BEM-020WO1 62. The gene modification system of any one of claims 58-61, wherein the gene modification efficacy is increased about 2 to 1000 fold.

63. The gene modification system of claim 62, wherein the gene modification efficacy is increased about 2 to 100 fold, or 2 to 50 fold, or 2 to 20 fold, or 10-50 fold.

64. The gene modification system of claim 63, wherein the gene modification efficacy is increased about 2 to10 fold, or 2 to 5 fold, or 3 to 8 fold, or 5-10 fold .

65. A composition comprising a single guide RNA of any one of claims 1-59.

66. The composition of claim 65, further comprising a Cas9 polypeptide, or variant thereof.

67. The composition of 66, wherein the Cas polypeptide is a Cas9 protein, dCas9 or a nickase.

68. The composition of any one of claims 65-67 is formulated in a lipid nanoparticle.

69. A method for modifying a target gene in a cell comprising introducing into the cell a gene editing system comprising a single guide RNA (sgRNA) of any one of claims 1-59.

70. The method of claim 66further comprising introducing into the cell a CRISPR-associated protein (Cas) polypeptide or variant thereof. wherein the sgRNA guides the Cas polypeptide to the target gene, and wherein the sgRNA induces modification of the target gene with an enhanced activity relative to a corresponding unmodified sgRNA comprising 5’GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAA CUUGAAAAAGUGGCACCGAGUCGGUGCUUUU 3’(SEQ ID NO: 19) 71. The method of claim 70, wherein the cell is a Cas9 expressing cell.

72. The method of any one of claims70-71, wherein the cell is a mammalian cell.

73. The method of any one of claims70-72, wherein the cell is an immune cell.

74. A kit comprising the sgRNA of any one of claims 1-57, the gene modification system of any one of claims 58-64, or the composition of any one of claims65-68.Attorney Docket No. BEM-020WO1 75. A single guide RNA comprising a sequence as set forth in any one of SEQ ID NOs: 20-21 and 51-52.